Dr. Elisha Fredman serves as a senior physician in Radiation Oncology, holding board certifications in both America and Israel. At Rabin Medical Center, Dr. Fredman oversees the radiation treatment of genitourinary cancer, encompassing prostate, bladder, kidney, and ureteral cancers. Additionally, he assumes the role of Director of Research and Innovation in Radiation Oncology. Prior to relocating to Israel, Dr. Fredman served as the Medical Director of Radiation Oncology at the Seidman Cancer Center, Geauga Medical Center of University Hospitals in Cleveland, OH.
Specializing in advanced treatment modalities such as stereotactic radiotherapy (e.g., SBRT or SABR) and brachytherapy, Dr. Fredman focuses on integrating radiation with systemic treatments. His clinical interests lie in delivering patient-centered care through the application of novel methods and technologies. Dr. Fredman's contributions to the field are evident through his authored articles and book chapters, as well as his leadership in multiple clinical trials aimed at enhancing radiation therapy for prostate and kidney cancer patients.
Selected publications from PubMed
Transcatheter Folded Valve Placement Within a Patent Ductus Arteriosus for Pulmonary Hypertension.
Fredman ES, Allam H, Varghese NP, Kobayashi D, Aggarwal M, Grady RM, Balzer D
JACC Case Rep. 2026 Jun 10;31(23):108137 doi: 10.1016/j.jaccas.2026.108137.
Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacing.
Fredman E, Attrash M, Yosefof E, Moore A, Tschernichovsky R, Bragilovski D, Weinstock-Sabbah M, Kindler J, Azuz RD, Radus R, Icht O, Golan S, Shochet T, Limon D
Radiother Oncol. 2026 Jun;219:111497 doi: 10.1016/j.radonc.2026.111497.
Simple, precise, and highly reproducible: Lenstar ocular biometry in mice.
Bratti AD, Banerjee S, Foley J, Johansson J, Niknahad A, Zeng A, Fredman E, Almehza Y, Rifat E, Taneja K, Han J, Zhang C, Anderson NK, Doyle JJ
Exp Eye Res. 2026 Jun;267:110937 doi: 10.1016/j.exer.2026.110937.
Intermediate-term oncological and functional outcomes of neoadjuvant 177-Lu-PSMA-I&T radionuclide treatment followed by radical prostatectomy.
Frumer M, Fredman E, Yakimov M, Kedar D, Baniel J, Groshar D, Rosenbaum E, Bernstine H, Golan S
World J Urol. 2026 Apr 3;44(1) pii: 274. doi: 10.1007/s00345-026-06314-3.
What We Give: Reflections From the Heart of Pediatric Cardiology.
Fredman ES
J Am Coll Cardiol. 2025 Nov 11;86(19):1752-1753 doi: 10.1016/j.jacc.2025.08.079.
Dr. Elisha Fredman (Israel) and his team at the Davidoff Cancer Center, Beilinson Hospital (Israel) will perform a SpaceOAR VueTM and fiducial marker insertion and answer all your questions.
With Boston Scientific
Published
Mar 2024
Surgery and Radiation therapy remain gold standard treatments for prostate cancer. Continued improvements in technique and technology further reduce the side effects associated with these very effective treatments.
With Boston Scientific
Published
Mar 2022
Help your network discover Dr. Elisha Fredman's clinical expertise.
